How effective is trastuzumab for injection?

Injectable trastuzumab (Trastuzumab) has shown good efficacy in the treatment of HER2-positive breast cancer and gastric/esophageal cancer. For patients with early-stage HER2-positive breast cancer, the use of trastuzumab combined with chemotherapy can significantly improve the treatment effect. Studies show that trastuzumab plus chemotherapy can significantly reduce the risk of tumor recurrence and death compared with chemotherapy alone. Additionally, this treatment regimen may increase a patient's chance of entering complete remission.

In the treatment of advanced HER2-positive breast cancer, trastuzumab is often used in combination with chemotherapy drugs. This combination treatment regimen has been shown to prolong survival, reduce the risk of tumor progression, and improve patients' quality of life. For patients with HER2-positive gastric/esophageal cancer, trastuzumab combined with chemotherapy also shows good efficacy. This treatment regimen can significantly extend patient survival and reduce tumor progression. The efficacy of trastuzumab may vary among individuals and may vary at different stages of disease and in specific circumstances.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.